Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-087-5 | CAS number: 1493-13-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
- Bacterial Reverse Mutation assay (Ames test): not mutagenic in
bacteria (Kr. 2, 1994)
- In vitro Mammalian chromosome aberration test: not clastogenic (Kr. 2,
1994)
- In vitro Mammalian Cell Gene Mutation test (Mouse Lymphoma Assay): not
mutagenic (Kr. 1, 2013)
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 18 Jun 2012 to 10 Jan 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- Thymidine kinase, TK+/-, locus of the L5178Y mouse lymphoma cell line.
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI 1640 with Horse serum, penicillin/streptomycin and sodium pyruvate
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically checked for karyotype stability: yes
- Periodically "cleansed" against high spontaneous background: yes - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor 1254 induced rat liver, S9
- Test concentrations with justification for top dose:
- Exp I: 1553, 777, 388, 194, 97, 49, 24 and 12 µg/mL (without S9/4 hours of exposure)
Exp I: 1563, 782, 391, 195, 98, 49, 24 and 12 µg/mL (with S9/ 4 hours of exposure)
Exp II: 1577, 789, 394, 197, 99, 49, 25 and 12 µg/mL (with and without S9/ 4 and 24 hours of exposure respectively) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Medium RPMI 1640 without supplements
- Justification for choice of solvent/vehicle: the test subtance was completely soluble, and this solvent doesn't have any effects on the viability of the cells. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Medium RPMI 1640 without supplements
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- With metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Medium RPMI 1640 without supplements
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- Without metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Preincubation period: not applicable
- Exposure duration: Exp I: 4 h (with and without metabolic activation), Exp II: 4h (with metabolic activation) and 24 h (without metabolic activation)
- Expression time (cells in growth medium): during 48 h after the end of the treatment period
- Selection time (if incubation with a selection agent): 10 days
SELECTION AGENT (mutation assays): 5-trifluorothymidine (TFT)
NUMBER OF REPLICATIONS: duplicate cultures
NUMBER OF CELLS EVALUATED: not applicable.The mutant frequency (MF) is calculated as : MF per survivor = [(-ln P(0) selective medium)/cells per well in selective medium)]/surviving fraction in non-selective medium.
DETERMINATION OF CYTOTOXICITY
- Method: cloning efficiency; relative total growth
OTHER EXAMINATIONS:
- Determination of polyploidy: not applicable
- Determination of endoreplication: not applicable
- Other: large and small colonies were scored. - Evaluation criteria:
- The test item is considered to have mutagenic effects if:
- the induced mutation frequency reproducibly exceeds a threshold of 126 colonies per 106 cells above the corresponding solvent control.
- the relative increase of the mutation frequency shows a dose relationship.
A mutagenic response is considered to be reproducible if it occurs in both parallel cultures.
Results of test groups are generally rejected if the relative total growth is less than 10% of the solvent control.
The biological relevance of the results is always considered first. Appropriate statistical methods are used as an aid in evaluating the test results. However, the results of statistical testing were assessed with respect to dose-response relationship. Reproducibility and historical data was also taken into consideration. - Statistics:
- - A linear regression (least squares) was performed to assess a possible dose dependent increase of mutant frequencies.
- Statistical significance was confirmed by means of the non-parametric X2 test. - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- (Not mutagenic), see tables 7.6.1/3 and 7.6.1/3
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- See below for more details
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: pH value was determined at the maximal concentration of the test item and in the solvent control with and without metabolic activation (See Table)
- Effects of osmolality: osmolality was determined at the maximal concentration of the test item and in the solvent control with and without metabolic activation (See Table 7.6.1/1)
- Evaporation from medium: no data
- Water solubility: no data
- Precipitation: no precipitation was observed in the treatments (Exp I + Exp II) with and without metabolic activation.
- Other confounding effects: none
RANGE-FINDING/SCREENING STUDIES:
the dose range of the test item used in the preliminary toxicity test was 0.014 mg/ml to 1.5 mg/ml. Based on the results of the solubility of the test item in aqueous media (0.9% NaCl solution and Medium RPMI 1640 without supplements) of the preliminary experiment, the highest concentration for the two main experiments was defined as 1.5 mg/mL. In addition, as no cytotoxicty was observed, the maximum concentration of the test item should be 0.01 mol/L (1.5 mg/ml) according to the regulatory guideline recommondations (OECD N° 473)
COMPARISON WITH HISTORICAL CONTROL DATA: yes. See Tables 7.6.1/4 and 7.6.1/5
ADDITIONAL INFORMATION ON CYTOTOXICITY: No cytotoxicity was observed at all tested concentrations (pre-experiment, Exp I and Exp II) with and without metabolic activation. - Conclusions:
- Interpretation of results:
negative with and without metabolic activation
Under the experimental conditions of this study, triflic acid did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation. Therefore, Trifluoromethanesulfonic acid is considered to be non-mutagenic under the conditions of the mouse lymphoma assay. - Executive summary:
In an vitro mammalian mutation assay (Andres, 2013), performed according to the OECD guideline N° 473 and in complinace with good laboratory practice, trifluoromethanesulfonic acid (purity >= 99%) diluted in Medium RPMI 1640 without supplements was tested in the L5178Y TK +/- mouse lymphoma cell line in the presence and the absence of mammalian metabolic activation (S9 mix).
Two independent experiments were performed. In experiment I, L5178Y TK +/- mouse lymphoma cells (heterozygous at the thymidine kinase locus) were treated with the test item at eight dose levels, in duplicate, together with vehicle (Medium RPMI 1640 without supplements) and positive controls (methylmethanesulphonate (MMS) or cyclophosphamide (CP) for the without and with metabolic activation respectively) using 4- hour exposure groups both in the absence and presenc of metabolic activation. In experiment II, the cells were treated with the test item at eight dose levels using a 4- hour exposure group in the presence of metabolic activation and a 24- hour exposure group in the absence of metabolic activation.
Based on the results of the solubility of the test item in aqueous media (0.9% NaCl solution and Medium RPMI 1640 without supplements) of the preliminary experiment, the highest concentration for the two main experiments was defined as 1.5 mg/mL. Based on this concentration seven further lower concentrations were also used in the assay (12 – 782 µg/ml).
None of the tested concentrations of the test item showed a cytotoxic effect on the cells. Furthermore, no substantial and reproducible dose dependent increase in mutant colony numbers was observed in both main experiments. No relevant shift of the ratio of small versus large colonies was observed up to the maximal concentration of the test item
The positive controls induced appropriate increases in mutant frequency in all mutation experiments thus demonstrating the activity of the S9 - mix and the validity of the assay.
In conclusion, it can be stated, that during the mutagenicity test described and under the experimental conditions reported, the test item did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation.Therefore,Trifluoromethanesulfonic acid is considered to be non-mutagenic under the conditions of the mouse lymphoma assay.
This study is considered as acceptable and satisfies the requirements for the mammalian mutagenicity endpoint.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From August 1, 1994 to November 2, 1994.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- yes
- Remarks:
- No data on pH, osmolality and precipitation
- Qualifier:
- according to guideline
- Guideline:
- other: Notification No.700 of the Planning and Coordination Bureau, Environment Agency (EA), No. 1039 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare (MHW) & No. 1014. MITI, 1986.
- Deviations:
- not specified
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- Not applicable
- Species / strain / cell type:
- other: Chinese hamster lung fibroblasts (CHL cells, clone No.11)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: Eagle's minimum essential medium, supplemented with 10% v/v newborn calf serum. The medium is hereafter referred to as 10% NCS/MEM.
- Properly maintained: no data
- Periodically checked for Mycoplasma contamination: no data
- Periodically checked for karyotype stability: no data
- Periodically "cleansed" against high spontaneous background: no data - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix from induced rat liver (Phenobarbital/5,6-benzoflavone)
- Test concentrations with justification for top dose:
- Preliminary toxicity assay:
- Direct method (without S9)/24: 0, 5, 10, 30, 50, 100, 300, 500, 1000 and 1500 µg/mL and 48 hours treatment: 0, 100, 300, 500 and 1500 µg/mL
- Metabolic activation method/24 and 48 hours treatment: 0, 10, 30, 50, 100, 300, 500, 1000 and 1500 µg/mL
Chromosomal aberration test:
- Direct method (without S9)/24 and 48 hours treatment: 0, 375, 750 and 1500 µg/mL
- Metabolic activation method:
* With S9 mix (6 hours): 0, 375, 750 and 1500 µg/mL
* Without S9 mix (6 hours): 0, 375, 750 and 1500 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: distilled water
- Justification for choice of solvent/vehicle: no data - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: with S9 mix: Mitomycin C (MMC), without S9 mix: Cyclophosphamide monohydrate (CPA, purity: 98.8%)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
Without metabolic activation:
- Exposure duration: 6 hours/24 hours/ 48 hours
- Expression time (cells in growth medium): 18 hours/0 hours/ 0 hours
- Fixation time (start of exposure up to fixation or harvest of cells): 24 hours/24 hours/ 48 hours
with metabolic activation:
- Exposure duration: 6 hours
- Expression time (cells in growth medium): 18 hours
- Fixation time (start of exposure up to fixation or harvest of cells): 24 hours
SPINDLE INHIBITOR (cytogenetic assays): Colcemid (final concentration 0.1 µg/mL)
STAIN (for cytogenetic assays): no data
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: 200 metaphases per concentration (100 from each duplicate culture)
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index and relative total growth
OTHER EXAMINATIONS:
- Determination of polyploidy: yes
- Determination of endoreplication: no data - Evaluation criteria:
- The results were judged as follows:
The incidence of cells (mean value for two dishes) with structural aberrations including gap or numerical aberration was:
- Less than 5%: negative (-)
- 5% or more, less than 10%: suspect positive (+/-)
- 10% or more, less than 20%: positive (+)
- 20% or more, less than 50%: positive (++)
- 50% or more: positive (+++)
The test substance was judged to be positive for the induction of the chromosomal aberrations when the incidence of cells with aberrations was dose-related or reproducible. - Statistics:
- Any statistical methods were not used.
- Key result
- Species / strain:
- mammalian cell line, other: Chinese hamster lung fibroblasts (CHL cells, clone No.11)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- determined in the preliminary test (See Table 7.6.1/1)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: no data
- Effects of osmolality: no data
- Evaporation from medium: no data
- Water solubility: freely soluble, no more details
- Precipitation: no data
RANGE-FINDING/SCREENING STUDIES:
The cell growth test and the cell division inhibition test were conducted to determine the concentrations of the test substance for the main test (See Table 7.6.1/1). Because of a weak cytotoxicity of the test substance, a concentration inhibiting 50% (IC50) of the cell growth was not found at the doses below 1500 µg/mL (10 mM) for 24 and 48 hours treatments of the direct method, while IC 50 in the metabolic activation method was approximately 1400 µg/mL. The maximum concentration of the test substance sufficient for assessing chromosomal aberration was 1500 µg/mL in every treatment methods. Therefore, the following 3 doses were employed for the chromosomal aberration test (direct method and metabolic activation method):
375, 750 and 1500 µg/mL
COMPARISON WITH HISTORICAL CONTROL DATA:
Solvent and positive control are in the range of historical control data
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Determined only in the preliminary study. described in the Table 7.6.1/1 and in the "Range-finding/screening studies" part. - Conclusions:
- Interpretation of results:
negative with and without metabolic activation
Under the test conditions, trifluoromethanesulphonic acid did not induce chromosome aberrations in Chinese hamster lung fibroblasts (CHL cells, clone No.11) in the presence and absence of metabolic activation. - Executive summary:
In an in vitro chromosome aberration test (Shozo Ogura, 1994), performed similarly to the OECD guideline N° 473 and in compliance with good laboratory practice, Chinese Hamster Lung fibroblasts (CHL cells, Clone N°11) were treated with trifluoromethanesulfonic acid at three dose levels and in each treatment condition, in duplicate, together with negative and positive controls. The dose range was selected on the basis of the results of a preliminary toxicity test and was 375, 750 and 1500 µg/ml for the 6 -hour treatments both with and without S9 and the 24 -hour and 48- hour continuous treatments without S9.
The negative controls gave frequencies of aberrations within the range expected for the CHL cell line. Positive controls induced the appropriate response. Chromosomal aberrations including the structural aberrations and the numerical aberrations were not induced up to 1500 µg/ml by the direct method and the metabolic activation method.
Under the test conditions, trifluoromethanesulfonic acid is not clastogenic with and without metabolic activation.
This study is considered as acceptable and satisfies the requirements for the cytogenicity endpoint.
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 6, 1994 to September 6, 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- yes
- Remarks:
- : only two replicates per concentration for the test substance were performed. No justification was done in the study report.
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Each strains derived from S.thyphimurium contains one mutation in the histidine operon, resulting in a requirement for histidine.
The amino acid requirement was determined as tryptophan for E. coli strain. See details in Table 7.6.1/1 - Species / strain / cell type:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvr A.
- Additional strain / cell type characteristics:
- other: additional mutation in uvrA, uvrB and rfa genes. The plasmid pKM101 was present in TA98 and TA100 in order to increase the sensibility of these strains to some mutagens. See details in Table 7.6.1/1.
- Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital/5,6-benzoflavone-pretreated male Sprague-Dawley rat liver S9 fraction.
- Test concentrations with justification for top dose:
- Preliminary test: 0 (vehicle), 50, 100, 200, 500, 1000, 2000 and 5000 µg/plate (+/-S9 mix)
Mutagenicity test: 0 (vehicle), 313, 625, 1250, 2500 and 5000 µg/plate (+/-S9mix) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: water
- Justification for choice of solvent/vehicle: no data - Untreated negative controls:
- yes
- Remarks:
- In the sterility test, after 0.1mL of each bacterial culture, the test substance solution, S9 mix and 0.1 M sodium phosphate buffer were smeared on a minimal glucose agar plate and incubated at 37 °C for 48 hours, bacterial contamination was checked.
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2), Sodium azide (NaN3), 2-Methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino]acridine. 2HCl (ICR-191) and 2-Aminoanthracene (2AA).
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation
DURATION:
- Preincubation period: 20 minutes at 37+/-0.5°C
- Exposure duration: 48 hours at 37+/-0.5°C
NUMBER OF REPLICATIONS: three plates were used for the negative control group and two plates for the test substance treatment group and for the positive control groups (+/-S9 mix).
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth - Evaluation criteria:
- A reproducible 2-fold increase in the number of revertants compared with the vehicle controls was considered as a positive result.
- Key result
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvr A.
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Observed at 5000 µg/plate in TA1535 and WP2uvrA (+/-S9 mix). The cytotoxicity was observed up to 1250 µg/plate in TA98 without S9mix and at 5000 µg/plate with S9mix.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS:
- Precipitation: no change was observed in the test substance solution within 2 hours after preparation except for heating of the solution when a 5 w/v% solution of the test substance was prepared.
- Other: the sterility test demonstrated that the test system was free from bacterial contamination.
RANGE-FINDING/SCREENING STUDIES: a preliminary study was performed on TA1535, TA100, WP2uvrA, TA98 and TA1537 with and without metabolic activation. The tested concentrations of the substance were 0, 50, 100, 200, 500, 1000, 2000, 5000 µg/plate. No cytotoxicty in terms of decrease of the number of revertants or effects on the bacterial lawn was observed.
COMPARISON WITH HISTORICAL CONTROL DATA: the numbers of revertant colonies in the positive controls and the negative control were within the range of background data in Hita laboratory.
ADDITIONAL INFORMATION ON CYTOTOXICITY: A slight growth inhibition wa observed at 5000 µg/plate for TA1535 and WP2uvrA (+/-S9mix) in the main test. The cytotoxicity was observed up to 1250 µg/plate in TA98 without S9mix and at 5000 µg/plate with S9mix. However, no statistically significant decreasing of revertant colonies was found. - Conclusions:
- Interpretation of results:
negative (with and without metabolic activation)
Under the test conditions, Trifluoromethanesulfonic acid did not show mutagenic activity in the bacterial mutation test with Salmonella typhimurium and E.Coli. - Executive summary:
In a reverse gene mutation assay in bacteria (YUKO, 1994), performed similarly to the OECD guideline No.471 and in compliance with Good Laboratory Practice,Salmonella typhimurium strain TA 1535, TA 1537, TA 98 and TA 100 and Escherichia coli strain WP2 uvrA were used in presence and in absence of metabolic activation system from liver fraction of phenobarbital/5,6 benzoflavone-induced rats (S9-mix). One preliminary study and one main test were performed using a preincubation method. The test article was dissolved in water and dose levels tested were included between 313 and 5000 µg/plate with or without S9‑mix. A slight growth inhibition was observed at 5000 µg/plate for TA1535 and WP2uvrA (+/-S9mix) and up to 1250 µg/plate in TA98 without S9 mix and at 5000 µg/plate with S9 mix. However, no statistically significant decreasing of revertant colonies was found.
The positive controls induced the appropriate responses in the corresponding strains. Under the experimental conditions of the study, Trifluoromethanesulfonic acid did not demonstrate any in vitro reverse mutagenic potential in either the presence or absence of metabolic activation.
This study is considered as acceptable as it satisfied the main criteria of the OECD guideline No.471.
Referenceopen allclose all
Table 7.6.1/1 Osmolarity and pH
|
Osmolarity in mOsmol/kg |
pH-Value |
Solvent control medium without supplements |
281 |
7.435 |
Solvent control 0.9 % NaCl in medium with supplements |
291 |
n.d. |
Positve control CPA in medium with supplements ,4.5 µg/mL |
287 |
7.522 |
Positve control MMS in medium with supplements, 19.5 µg/mL |
385 |
7.523 |
Test Item in medium with supplements; 1.577 mg/mL |
294 |
7.025 |
Test Item in medium with supplements; 0.1 mg/mL |
287 |
7.485 |
Table 7.6.1/2 the cytotoxicity and mutagenicity results Exp I
Treatment |
Conc. (µg/ml) |
Relative Total Growth Culture A |
Mutants per 106 cells Culture A |
Relative Total Growth Culture B |
Mutants per 106 cells Culture B |
Relative Total Growth Mean |
Mutants per 106 cells Mean |
Exp. I without metabolic activation (-S9), exposition time 4 hours |
|||||||
Solvent control medium |
-- |
-- |
168.5 |
-- |
191 |
-- |
179.75 |
Positive control MMS |
19.5 |
33.7% |
583.5 |
20.3% |
588 |
27.0% |
585.75 |
Test Item |
1553 |
86.9% |
150.5 |
91.6% |
202 |
89.2% |
176.25 |
Test Item |
777 |
105.8% |
157 |
82.8% |
221.5 |
94.3% |
189.25 |
Test Item |
388 |
94.9% |
214 |
91.6% |
267.5 |
93.3% |
240.75 |
Test Item |
194 |
96.7% |
175 |
108.2% |
232 |
102.5% |
203.5 |
Test Item |
97 |
95.2% |
172 |
106.4% |
215.5 |
100.8% |
193.75 |
Test Item |
49 |
117.0% |
176 |
81.7% |
227.5 |
99.3% |
201.75 |
Test Item |
24 |
106.1% |
177.5 |
100.5% |
225.5 |
103.3% |
201.5 |
Test Item |
12 |
113.0% |
178.5 |
103.6% |
210.5 |
108.3% |
194.5 |
Exp. I with metabolic activation (+S9), exposition time 4 hours |
|||||||
Solvent control medium |
-- |
-- |
78 |
-- |
95.5 |
-- |
86.75 |
Solvent control 0.9% NaCl |
-- |
-- |
46.5 |
-- |
70.5 |
-- |
58.5 |
Positive control CPA |
4.5 |
29.5% |
797.5 |
28.7% |
407.5 |
29.1% |
602.5 |
Test Item |
1563 |
102.2% |
151 |
97.5% |
172.5 |
99.8% |
161.75 |
Test Item |
782 |
133.6% |
120 |
93.0% |
149 |
113.3% |
134.5 |
Test Item |
391 |
100.2% |
152 |
90.3% |
131 |
95.2% |
141.5 |
Test Item |
195 |
125.2% |
92.5 |
152.2% |
134.5 |
138.7% |
113.5 |
Test Item |
98 |
141.7% |
108 |
81.4% |
136 |
111.6% |
122 |
Test Item |
49 |
119.5% |
102.5 |
86.4% |
167.5 |
103.0% |
135 |
Test Item |
24 |
161.8% |
107.5 |
86.5% |
175.5 |
124.1% |
141.5 |
Test Item |
12 |
95.4% |
128 |
64.9% |
197 |
80.1% |
162.5 |
Values above threshold (see below) are given in bold characters.
Threshold for mutagenic effects: number of mutant colonies per 106cells of the respective solvent control plus 126.
Threshold solvent contr. (medium) (-S9): 305.75 mutants/106cells
Threshold solvent contr. (medium) (+S9): 212.75 mutants/106cells
Table 7.6.1/3 the cytotoxicity and mutagenicity results Exp II
Treatment |
Conc. (µg/ml) |
Relative Total Growth Culture A |
Mutants per 106 cells Culture A |
Relative Total Growth Culture B |
Mutants per 106 cells Culture B |
Relative Total Growth Mean |
Mutants per 106 cells Mean |
Exp. II without metabolic activation (-S9), exposition time 24 hours |
|||||||
Solvent control medium |
-- |
-- |
118.5 |
-- |
134.5 |
-- |
126.5 |
Positive control MMS |
19.5 |
16.9% |
736.5 |
14.4% |
953 |
15.7% |
844.75 |
Test Item |
1577 |
98.4% |
123 |
106.4% |
105 |
102.4% |
114 |
Test Item |
789 |
121.6% |
102 |
112.6% |
120 |
117.1% |
111 |
Test Item |
394 |
133.3% |
85 |
136.0% |
88.5 |
134.6% |
86.75 |
Test Item |
197 |
98.5% |
108 |
98.8% |
152 |
98.7% |
130 |
Test Item |
99 |
85.7% |
156.5 |
119.3% |
95.5 |
102.5% |
126 |
Test Item |
49 |
103.4% |
123 |
108.9% |
116 |
106.1% |
119.5 |
Test Item |
25 |
121.3% |
85 |
115.3% |
92 |
118.3% |
88.5 |
Test Item |
12 |
116.9% |
124.5 |
116.2% |
86 |
116.5% |
105.25 |
Exp. II with metabolic activation (+S9), exposition time 4 hours |
|||||||
Solvent control medium |
-- |
-- |
98 |
-- |
116.5 |
-- |
107.25 |
Solvent control 0.9% NaCl |
|
-- |
114.5 |
-- |
135.5 |
-- |
125 |
Positive control CPA |
4.5 |
23.1% |
844 |
84.3% |
697.5 |
28.7% |
770.75 |
Test Item |
1577 |
116.5% |
112 |
121.3% |
160.5 |
118.9% |
136.25 |
Test Item |
789 |
87.6% |
146 |
124.8% |
146.5 |
106.2% |
146.25 |
Test Item |
394 |
72.6% |
179 |
98.9% |
177.5 |
85.7% |
178.25 |
Test Item |
197 |
97.7% |
128.5 |
113.5% |
170 |
105.6% |
149.25 |
Test Item |
99 |
81.1% |
142 |
135.7% |
142.5 |
108.4% |
142.25 |
Test Item |
49 |
58.9% |
143 |
126.3% |
118 |
92.6% |
130.5 |
Test Item |
25 |
89.2% |
129 |
132.7% |
142.5 |
110.9% |
135.75 |
Test Item |
12 |
101.5% |
126 |
124.5% |
179 |
113% |
152.5 |
Values above threshold (see below) are given in bold characters.
Threshold for mutagenic effects: number of mutant colonies per 106cells of the respective solvent control plus 126.
Threshold solvent contr. (medium) (-S9): 252.5 mutants/106cells
Threshold solvent contr. (medium) (+S9): 233.25 mutants/106cells
Table 7.6.1/4 Historical Data for the Experiments with Metabolic Activation
Parameter |
mutant frequency of |
Mean |
646.38 |
Standard Deviation |
175.31 |
Range (min – max) |
359.0 - 994.0 |
Study 12032101G880 First Experiment |
602.5 |
Study 12032101G880 Second Experiment |
770.75 |
Table 7.61/5 Historical Data for the Experiments without Metabolic Activation
Parameter |
mutant frequency of |
Mean |
717.96 |
Standard Deviation |
340.54 |
Range (min – max) |
317.5 - 1363.0 |
Study 12032101G880 First Experiment |
585.75 |
Study 12032101G880 Second Experiment |
844.75 |
Table 7.6.1/3: Number of revertants per plate (mean of duplicates) in the absence of metabolic activation in finding test (preincubation method)
PFC-MS Concentration |
TA 100 |
TA1535 |
WP2uvrA |
TA 98 |
TA 1537 |
|||||
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
|
0* |
112 |
- |
12 |
- |
43 |
- |
24 |
- |
8 |
- |
50 |
133 |
- |
13 |
- |
54 |
- |
28 |
- |
8 |
- |
100 |
120 |
- |
13 |
- |
56 |
- |
26 |
- |
8 |
- |
200 |
129 |
- |
15 |
- |
56 |
- |
25 |
- |
15 |
- |
500 |
116 |
- |
16 |
- |
54 |
- |
20 |
- |
10 |
- |
1000 |
129 |
- |
14 |
- |
49 |
- |
26 |
- |
14 |
- |
2000 |
122 |
- |
18 |
- |
51 |
- |
23 |
- |
10 |
- |
5000 |
118 |
- |
13 |
- |
59 |
- |
30 |
- |
14 |
- |
Positive control** |
477 |
- |
333 |
- |
591 |
- |
463 |
- |
1913 |
- |
Table 7.6.1/4:Number of revertants per plate (mean of duplicates) in the presence of metabolic activation in finding test (preincubation method)
PFC-MS Concentration |
TA 100 |
TA1535 |
WP2uvrA |
TA 98 |
TA 1537 |
|||||
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
|
0* |
124 |
- |
10 |
- |
61 |
- |
33 |
- |
17 |
- |
50 |
142 |
- |
12 |
- |
64 |
- |
36 |
- |
23 |
- |
100 |
135 |
- |
14 |
- |
58 |
- |
36 |
- |
16 |
- |
200 |
123 |
- |
17 |
- |
82 |
- |
36 |
- |
22 |
- |
500 |
117 |
- |
12 |
- |
78 |
- |
36 |
- |
27 |
- |
1000 |
123 |
- |
11 |
- |
66 |
- |
32 |
- |
23 |
- |
2000 |
127 |
- |
13 |
- |
77 |
- |
26 |
- |
24 |
- |
5000 |
149 |
- |
15 |
- |
55 |
- |
31 |
- |
22 |
- |
Positive control** |
501 |
- |
160 |
- |
425 |
- |
188 |
- |
93 |
- |
Table 7.6.1/5:Number of revertants per plate (mean of duplicates) in the absence of metabolic activation in Main test (preincubation method)
PFC-MS Concentration |
TA 100 |
TA1535 |
WP2uvrA |
TA 98 |
TA 1537 |
|||||
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
|
0* |
116 |
- |
10 |
- |
39 |
- |
26 |
- |
13 |
- |
313 |
123 |
- |
13 |
- |
46 |
- |
22 |
- |
22 |
- |
625 |
134 |
- |
12 |
- |
39 |
- |
24 |
- |
19 |
- |
1250 |
116 |
- |
9 |
- |
42 |
- |
14* |
- |
23 |
- |
2500 |
121 |
- |
12 |
- |
43 |
- |
15* |
- |
16 |
- |
5000 |
117 |
- |
9* |
- |
38* |
- |
16* |
- |
19 |
- |
Positive control** |
282 |
- |
225 |
- |
439 |
- |
490 |
- |
1553 |
- |
Table 7.6.1/6: Number of revertants per plate (mean of duplicates) in the presence of metabolic activation in Main test (preincubation method)
PFC-MS Concentration |
TA 100 |
TA1535 |
WP2uvrA |
TA 98 |
TA 1537 |
|||||
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
Mean |
Standard deviation |
|
0* |
119 |
- |
13 |
- |
55 |
- |
23 |
- |
18 |
- |
313 |
134 |
- |
13 |
- |
44 |
- |
26 |
- |
21 |
- |
625 |
144 |
- |
16 |
- |
46 |
- |
26 |
- |
19 |
- |
1250 |
142 |
- |
8 |
- |
41 |
- |
27 |
- |
16 |
- |
2500 |
127 |
- |
14 |
- |
40 |
- |
19 |
- |
15 |
- |
5000 |
139 |
- |
7* |
- |
32* |
- |
20* |
- |
19 |
- |
Positive control** |
546 |
- |
162 |
- |
426 |
- |
189 |
- |
88 |
- |
*Solvent control = negative control: water
**Mutagens positive controls (-S9 mix):
- AF-2 (0.01 µg/plate) in TA100 and WP2 uvrA and (0.1 µg/plate) in TA98
- NaN3 (0.5 µg/plate) in TA1535
- ICR-191(1µg/plate) in TA1537
**Mutagens positive controls (+S9 mix):
- 2AA: (2 µg/plate) in TA1535 and TA1537, (1µg/plate) in TA100, (0.5µg/plate) in TA98 and (10 µg/plate) in WP2 uvrA.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Bacterial Reverse Mutation assay:
One reverse bacterial gene mutation test (YUKO, 1994) was selected as a key study, (OECD 471, Kr: 2). In this study, Trifluoromethanesulphonic acid is not mutagenic in S. typhimurium strains TA1535, TA1537, TA98 and TA100 and E. coli strain WP2uvrA- with and without metabolic activation, up to a limit concentration.These results are confirmed by a supporting study (Cinelli, 2003), (OECD 471 screening, Kr: 2) providing negative results with or without metabolic activation inS. typhimurium strains TA98, TA100. Therefore, Trifluoromethanesulphonic acid showed no mutagenic action in Bacteria.
In vitro Mammalian chromosome aberration test:
In vitro, one cytogenetic study in CHL cells (OECD 473, Kr: 2) was available and was selected as the key study (Shozo Ogura, 1994). Chinese Hamster Lung fibroblasts (CHL cells, Clone N°11) were treated with trifluoromethanesulphonic acid at three dose levels, in each treatment case, in duplicate, together with negative and positive controls. The dose range was selected on the basis of the results of a preliminary toxicity test and was 375, 750 and 1500 µg/ml for the 6 -hour treatments both with and without S9 and the 24 -hour and 48- hour continuous treatments without S9.
The negative controls gave frequencies of aberrations within the range expected for the CHL cell line. Positive controls induced the appropriate response. Chromosomal aberrations including the structural aberrations and the numerical aberrations were not induced up to 1500 µg/ml by the direct method and the metabolic activation method.
Under the test conditions, trifluoromethanesulphonic acid is not clastogenic with and without metabolic activation.
In vitro Mammalian Cell Gene Mutation test:
One study was available and was considered as the key study.
An in vitro mammalian mutation assay (Andres, 2013), performed according to the OECD guideline N° 473 and in compliance with good laboratory practice, trifluoromethanesulphonic acid (purity >= 99%) diluted in Medium RPMI 1640 without supplements was tested in the L5178Y TK +/- mouse lymphoma cell line in the presence and the absence of mammalian metabolic activation (S9 mix).
Two independent experiments were performed. In experiment I, L5178Y TK +/- mouse lymphoma cells (heterozygous at the thymidine kinase locus) were treated with the test item at eight dose levels, in duplicate, together with vehicle (Medium RPMI 1640 without supplements) and positive controls (methylmethanesulphonate (MMS) or cyclophosphamide (CP) for without and with metabolic activation respectively) using 4- hour exposure groups both in the absence and presence of metabolic activation. In experiment II, the cells were treated with the test item at eight dose levels using a 4- hour exposure group in the presence of metabolic activation and a 24- hour exposure group in the absence of metabolic activation.
Based on the results of the solubility of the test item in aqueous media (0.9% NaCl solution and Medium RPMI 1640 without supplements) of the preliminary experiment, the highest concentration for the two main experiments was defined as 1.5 mg/mL. Based on this concentration seven further lower concentrations were also used in the assay (12 – 782 µg/ml).
None of the tested concentrations of the test item showed a cytotoxic effect on the cells. Furthermore, no substantial and reproducible dose dependent increase in mutant colony numbers was observed in both main experiments. No relevant shift of the ratio of small versus large colonies was observed up to the maximal concentration of the test item.
The positive controls induced appropriate increases in mutant frequency in all mutation experiments thus demonstrating the activity of the S9 - mix and validity of the assay.
Under the experimental conditions reported in this study, the test item did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation.Therefore,Trifluoromethanesulphonic acid is considered to be non-mutagenic under the conditions of the mouse lymphoma assay.
In conclusion: based on all these studies, trifluoromethanesulphonic acid is considered as not genotoxic.
Justification for classification or non-classification
Regarding on the overall negative results from the in vitro genotoxicity studies, it is likely that trifluoromethanesulphonic acid doesn't present genotoxic activity potential, therefore no classification is required according to the CLP Regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.